Investment Thesis
VG Life Sciences exhibits critical financial distress with zero revenue, negative stockholders' equity of -$4.3M, and only $22.9K in cash reserves. The company is technically insolvent with liquidity ratios near zero (0.01x), indicating inability to meet near-term obligations without immediate capital infusion. Continued losses of $3.9M net income and $361.7K capital expenditures are unsustainable.
Strengths
- Pharmaceutical sector offers potential for breakthrough products if pipeline exists
- Modest asset base of $1.1M provides some liquidation value
- No significant long-term debt burden relative to equity
Risks
- Zero revenue generation - no commercial operations despite 10+ years in market
- Negative stockholders' equity indicates technical insolvency
- Critically low liquidity (0.01x current ratio) with only $22.9K cash
- Severe cash burn unsustainable without continuous external funding
- Financial data is 10+ years old (2015-09-30) - operational status unclear
- Zero insider activity in past 90 days suggests potential company abandonment
Key Metrics to Watch
- Revenue and sales - must demonstrate viable product commercialization
- Updated SEC filings - need current financial statements to assess ongoing viability
- Cash position and monthly burn rate - survival timeline without funding
- Path to positive stockholders' equity - structural insolvency must be addressed
Financial Metrics
Revenue
0.0
Net Income
-3.9M
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
1.1M
Cash
22.9K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-346.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.01x
Quick Ratio
0.01x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
-1.56x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T15:06:20.243068 |
Data as of: 2015-09-30 |
Powered by Claude AI